AMiDot®
Designed • Developed • Manufactured
The analytical protein microarray system to detect, identify and quantify autoantibodies in sera.
AMiDot® is a protein microarray-based fluorescent immunoassay developed to allow simultaneous detection of multiple autoantibodies on a single patient. It is designed to bridge between screening patients using IFA pattern recognition and secondary antigen characterisation.
The AMiDot® microarray is printed on glass slides compatible with current IFA slides, sample dilution and incubation times enabling them to be run on automated IFA processors at the same time as standard HEp2 and tissue IFA slides.
Each AMiDot® well consists of a 9 x 9 microarray containing calibration, process controls, registration dots and up to 20 different autoimmune antigens.
5 Autoimmune panels covering Systemic Autoimmmune Disease, Autoimmune Vasculitis, Idiopathic Inflammatory Myopathies, Gastrointestinal Autoimmune Disease and Liver Autoimmune Disease are manufactured by CLS for A. Menarini Diagnostics in Europe.
Any protein microarray can be developed and manufactured such as infectious diseases.
Feasibility proven with protein microarray for Lyme Disease.
Cambridge Life Sciences (CLS) have demonstrated the feasibility to produce a Lyme Disease microarray using antigens P100, P66, P58, P45, P41, P39 (BmpA), P31 (OspA), P30, P28, P23 (OspC), P18 (DpbA) associated with the detection of Lyme Disease on their autoimmune AMiDot® microarray platform using both anti-human IgG and IgM conjugates. The data demonstrates that a distinction can be made between positive and negative samples and that a positive result was obtained with the control sera for the specific Lyme Disease antigens. There is no background signal and no response from normal human sera using the AMiDot® reagents which results in a sensitive and specific assay.
Please contact us at info@clsdiagnostics.com for collaborative opportunities.